Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
3.810
+0.080 (2.14%)
At close: Oct 8, 2026, 4:00 PM EDT
3.750
-0.060 (-1.57%)
After-hours: Oct 8, 2026, 7:51 PM EDT
Bicycle Therapeutics Revenue
Bicycle Therapeutics had revenue of $629.00K in the quarter ending June 30, 2026, a decrease of -78.46%. This brings the company's revenue in the last twelve months to $61.21M, up 217.44% year-over-year. In the year 2025, Bicycle Therapeutics had annual revenue of $72.59M with 105.77% growth. That makes Bicycle Therapeutics the 26,415th largest company in the world by revenue and 3,631st in the United States.
Revenue (ttm)
$61.21M
Revenue Growth
+217.44%
P/S Ratio
4.36
Revenue / Employee
$212,517
Employees
288
Market Cap
266.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.59M | 37.31M | 105.77% |
| Dec 31, 2024 | 35.28M | 8.30M | 30.76% |
| Dec 31, 2023 | 26.98M | 12.51M | 86.52% |
| Dec 31, 2022 | 14.46M | 2.77M | 23.65% |
| Dec 31, 2021 | 11.70M | 1.31M | 12.58% |
| Dec 31, 2020 | 10.39M | -3.41M | -24.72% |
| Dec 31, 2019 | 13.80M | 6.67M | 93.40% |
| Dec 31, 2018 | 7.14M | 5.08M | 246.41% |
| Dec 31, 2017 | 2.06M | - | - |
| Dec 31, 2016 | 0 | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Abeona Therapeutics | 25.52M |
| X4 Pharmaceuticals | 15.85M |
| Fate Therapeutics | 6.49M |
| EyePoint | 2.79M |
| SAB Biotherapeutics | 114.70K |
BCYC News
- 16 days ago - Bicycle Therapeutics treatment of pancreatic cancer granted orphan designation - TheFly
- 2 months ago - Visa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatch - PYMNTS
- 2 months ago - Bicycle Therapeutics assumed with an Outperform at Oppenheimer - TheFly
- 2 months ago - Bicycle Therapeutics reports Q2 EPS (72c), consensus (58c) - TheFly
- 2 months ago - Bicycle Therapeutics sees cash runway into 2030 - TheFly
- 2 months ago - Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Business Wire
- 2 months ago - Bicycle Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Bicycle Therapeutics Earnings release: Q2 2026 - Filings